FDA Issues Draft Guidance on Cybersecurity for Medical Devices

The Food and Drug Administration (FDA) has released a draft guidance proposing revisions to the “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions” document. This draft seeks to incorporate specific updates into the existing Premarket Cybersecurity Guidance, aligning with the agency’s current perspectives. These revisions stem from Section 3305 of the Food and Drug Omnibus Reform Act of 2022, which introduced section 524B, “Ensuring Cybersecurity of Medical Devices,” into the FD&C Act. 

What does the proposed draft guidance outline? 

• • Submission Requirements: Requirements for manufacturers submitting premarket applications for “cyber devices,” defined as those containing sponsor-validated software, internet connectivity, and vulnerability to cybersecurity threats. 
  • Key Documentation: It emphasizes the significance of thorough documentation to meet cybersecurity standards, encompassing plans for vulnerability monitoring and disclosure, cybersecurity processes, and providing a Software Bill of Materials (SBOM).
  • FDA Evaluation Criteria: The guidance distinguishes between modifications to cyber devices that affect cybersecurity and those that do not. As part of its evaluation process for premarket submissions, the FDA scrutinizes cybersecurity aspects to guarantee the safety and effectiveness of the devices. 

You can read the full guidance document here. 

The draft guidance is available for public comment, demonstrating the FDA’s dedication to involving stakeholders in shaping regulatory frameworks for medical device cybersecurity. The dateline for companies to submit their comments is May 13th, 2024.

Learn how MedEnvoy can assist you:

• • US FDA Consulting Services
  • US FDA Agent
  • Premarket Approval (PMA)
  • US FDA 510(k) Compilation and Consulting